logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
S

Shigeo Shimose

Kurume University School of Medicine
H指数:28
被引数:2,235

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Early Changes in Lymphocyte Counts Predict Clinical Outcomes in Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab

durvalumab联合tremelimumab治疗肝细胞癌患者淋巴细胞计数早期变化可预测临床结局

Journal of Gastroenterology and Hepatology
IF3.4
2026-10-070
OAAI
Yuichi Honma; Shigeo Shimose; Takanori Ito; Issei Saeki; Joji Tani; Takanori Matsuura; Tetsu Tomonari; Yasuto Takeuchi; Nobuhito Taniki; Kyo Sasaki; Ryu Sasaki; Takeshi Hatanaka; Satoru Kakizaki; Naoki Yoshioka; Takehito Naito; Mamiko Takeuchi; Tetsuya Yasunaka; Masahiro Sakata; Hideki Iwamoto; Tomotake Shirono; Satoshi Itano; Norikazu Tanabe; Takafumi Yamamoto; Atsushi Naganuma; Yuki Kanayama; Hisamitsu Miyaaki; Sohji Nishina; Nobuhiro Nakamoto; Motoyuki Otsuka; Tetsuji Takayama; Yuzo Kodama; Hideki Kobara; Taro Takami; Hiroki Kawashima; Takumi Kawaguchi; Masaru Harada
Early and Late Survival Dynamics of Immunotherapy Combinations in Advanced HCC: Anchored Indirect Comparison of Atezolizumab plus Bevacizumab versus Durvalumab + Tremelimumab

晚期肝细胞癌免疫疗法联合方案的早期与晚期生存动态：阿替利珠单抗联合贝伐珠单抗与度伐利尤单抗联合特瑞普利单抗的锚定间接比较

European Journal of Cancer
IF7.1
2026-04-210
PRE
Andrea Casadei-Gardini; Terry Cheuk-Fung Yip; Alessandro Vitale; Federico Rossari; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Fabio Piscaglia; Takashi Kumada; Mario Scartozzi; Emiliano Tamburini; Francesco Giuseppe Foschi
Conversion Hepatectomy After New FP Therapy for Malignant Hepatocellular Neoplasm, Not Otherwise Specified: A Case Report

恶性肝细胞肿瘤（Not Otherwise Specified）经新FP疗法后行转化性肝切除术：一例病例报告

Hepatology Research
IF3.4
2026-02-240
PRE
Etsuko Moriyama; Hironori Koga; Takashi Niizeki; Hideki Iwamoto; Shigeo Shimose; Tomotake Shirono; Takahiko Tokushige; Masahito Nakano; Ryoko Kuromatsu; Toru Goto; Masaki Honda; Taizo Hibi; Yoshiki Mikami; Reiichiro Kondo; Jun Akiba; Takumi Kawaguchi
Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class B

阿特珠单抗联合贝伐珠单抗在Child-Pugh B级肝细胞癌患者中的有效性与安全性

LIVER INTERNATIONAL
IF5.2
2025-11-280
OAAI
Sasaki, Ryu; Shimose, Shigeo; Saeki, Issei; Ito, Takanori; Takeuchi, Yasuto; Tani, Joji; Tomonari, Tetsu; Sasaki, Kyo; Kakizaki, Satoru; Hatanaka, Takeshi; Miuma, Satoshi; Shirono, Tomotake; Iwamoto, Hideki; Tanabe, Norikazu; Yamamoto, Takafumi; Kanayama, Yuki; Naganuma, Atsushi; Nishina, Sohji; Takayama, Tetsuji; Kobara, Hideki; Otsuka, Motoyuki; Kawashima, Hiroki; Takami, Taro; Kawaguchi, Takumi; Miyaaki, Hisamitsu
Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENT

阿替利珠单抗联合贝伐珠单抗用于不适合TACE治疗的超出Up-To-7标准的中间阶段肝癌：REPLACEMENT研究的最终分析

Liver International
IF5.2
2025-11-030
OAAI
Kazuomi Ueshima; Kaoru Tsuchiya; Tatsuya Yamashita; Shigeo Shimose; Kazushi Numata; Yuzo Kodama; Shinji Itoh; Yasuhito Tanaka; Hidekatsu Kuroda; Kazuyoshi Ohkawa; Teiji Kuzuya; Masafumi Ikeda; Youhei Kooka; Hiroshi Aikata; Atsushi Hiraoka; Michihisa Moriguchi; Ryosuke Tateishi; Sadahisa Ogasawara; Kouji Yamamoto; Masatoshi Kudo
Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma

不可切除肝细胞癌患者接受阿特珠单抗联合贝伐珠单抗治疗后序贯免疫检查点抑制剂再治疗的结局

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
IF3.4
2025-11-010
OAAI
Ito, Takanori; Shimose, Shigeo; Saeki, Issei; Takeuchi, Yasuto; Tani, Joji; Tomonari, Tetsu; Sasaki, Ryu; Sasaki, Kyo; Kakizaki, Satoru; Hatanaka, Takeshi; Iwamoto, Hideki; Tanabe, Norikazu; Yamamoto, Takafumi; Naganuma, Atsushi; Shirono, Tomotake; Kanayama, Yuki; Miyaaki, Hisamitsu; Nishina, Sohji; Takayama, Tetsuji; Kobara, Hideki; Otsuka, Motoyuki; Takami, Taro; Kawaguchi, Takumi; Kawashima, Hiroki
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi-Center Real-World Study

仑伐替尼与索拉非尼在肝移植后复发性HCC中的疗效与安全性比较：一项多中心真实世界研究

HEPATOLOGY RESEARCH
IF3.4
2025-11-010
PRE
Lo Prinzi, Federica; Rossari, Federico; De Rosa, Antonio; Vivaldi, Caterina; Kudo, Masatoshi; Shimose, Shigeo; Suda, Goki; Camera, Silvia; Foti, Silvia; Rizzato, Mario Domenico; Salani, Francesca; Nishida, Naoshi; Shirono, Tomotake; Sakamoto, Naoya; Passeri, Laura; Ferrara, Michele; Solda, Caterina; Cesario, Silvia; Ueshima, Kazuomi; Niizeki, Takashi; Sho, Takuya; Persano, Mara; Vitiello, Francesco; Invernizzi, Federica; Lonardi, Sara; Masi, Gianluca; Rimini, Margherita; Gardini, Andrea Casadei
Association of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study

代谢相关脂肪性肝病与度伐利尤单抗和特瑞普利单抗在晚期肝细胞癌患者临床结局中的关联：一项多中心研究

Hepatology Research
IF3.4
2025-08-210
PRE
Takeshi Hatanaka; Shigeo Shimose; Takanori Ito; Joji Tani; Tetsu Tomonari; Issei Saeki; Yasuto Takeuchi; Kyo Sasaki; Yuichi Honma; Ryu Sasaki; Naoki Yoshioka; Takehito Naito; Mamiko Takeuchi; Tetsuya Yasunaka; Masahiro Sakata; Hideki Iwamoto; Satoshi Itano; Yuki Kanayama; Tomotake Shirono; Norikazu Tanabe; Takafumi Yamamoto; Atsushi Naganuma; Sohji Nishina; Motoyuki Otsuka; Hideki Kobara; Taro Takami; Tetsuji Takayama; Takumi Kawaguchi; Hiroki Kawashima; Masaru Harada; Hisamitsu Miyaaki; Satoru Kakizaki; Hepatology InVestigator Experts in Japan (HIVE-J) Study Group
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population

阿特珠单抗联合贝伐珠单抗与仑伐替尼对比用于巴塞罗那临床肝癌分期B期（BCLC-B）肝细胞癌（HCC）患者：一项真实世界人群研究

Seminars in Oncology
IF2.5
2025-06-090
PRE
Francesco Vitiello; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Francesco Tovoli; Takashi Kumada; Mario Scartozzi; Emiliano Tamburini; Francesco Giuseppe Foschi; Mara Persano; Federico Rossari; Silvia Foti; Margherita Rimini
Comparison Analysis of Lenvatinib Plus Transcatheter Arterial Chemoembolization Versus Atezolizumab Plus Bevacizumab as First-Line Therapy for Intermediate-Stage Hepatocellular Carcinoma Beyond the Up-to-Seven Criteria

仑伐替尼联合经导管动脉化疗栓塞与阿替利珠单抗联合贝伐珠单抗作为超出“七限”标准的中间期肝细胞癌的一线治疗比较分析

Journal of Gastroenterology and Hepatology
IF3.4
2025-05-310
PRE
Takashi Niizeki; Seiichi Mawatari; Michihiko Shibata; Ryu Sasaki; Shinji Itoh; Satoshi Shakado; Rie Sugimoto; Yusuke Morita; Takuya Kuwashiro; Mizuki Endo; Masao Iwao; Yasuhide Motoyoshi; Masahito Nakano; Shigeo Shimose; Hirokazu Takahashi; Hiroshi Yatsuhashi; Fumihito Hirai; Tomoharu Yoshizumi; Hisamitsu Miyaaki; Takumi Kawaguchi; Akio Ido; Masaru Harada
The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan
HEPATOLOGY INTERNATIONAL
IF6.1
2025-02-280
PRE
Shimose, Shigeo; Saeki, Issei; Ito, Takanori; Takeuchi, Yasuto; Tani, Joji; Tomonari, Tetsu; Sasaki, Ryu; Sasaki, Kyo; Kakizaki, Satoru; Hatanaka, Takeshi; Iwamoto, Hideki; Tanabe, Norikazu; Yamamoto, Takafumi; Naganuma, Atsushi; Shirono, Tomotake; Kanayama, Yuki; Nishina, Sohji; Takayama, Tetsuji; Kobara, Hideki; Otsuka, Motoyuki; Kawashima, Hiroki; Takami, Taro; Kawaguchi, Takumi; Hepatology InVestigator Experts Japan HIVE-J Study Grp
Antitumor effects and immune-mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma

durvalumab联合tremelimumab治疗不可切除的肝细胞癌的抗肿瘤作用和免疫介导的不良事件

HEPATOLOGY RESEARCH
IF3.4
2024-12-150
OA
Ito, Takanori; Shimose, Shigeo; Tani, Joji; Tomonari, Tetsu; Saeki, Issei; Takeuchi, Yasuto; Hatanaka, Takeshi; Sasaki, Kyo; Kakizaki, Satoru; Kanayama, Yuki; Yoshioka, Naoki; Naito, Takehito; Takeuchi, Mamiko; Yasunaka, Tetsuya; Sakata, Masahiro; Iwamoto, Hideki; Itano, Satoshi; Shirono, Tomotake; Tanabe, Norikazu; Yamamoto, Takafumi; Naganuma, Atsushi; Nishina, Sohji; Otsuka, Motoyuki; Takami, Taro; Takayama, Tetsuji; Kawaguchi, Takumi; Kawashima, Hiroki
Final analysis of the REPLACEMENT study: a phase II study of atezolizumab plus bevacizumab (atezo plus bev) for patients (pts) with Transcatheter arterial chemoembolization (TACE)-unsuitable intermediate-stage hepatocellular carcinoma (HCC) beyond the up-to-seven criteria

REPLACEMENT研究的最终分析：一项关于阿替利珠单抗联合贝伐珠单抗（atezo plus bev）治疗经肝动脉化疗栓塞（TACE）不适宜的超出“七例标准”的中期肝细胞癌（HCC）患者的II期研究

ANNALS OF ONCOLOGY
IF65.4
2024-12-011
PRE
Yamashita, T.; Ueshima, K.; Tsuchiya, K.; Kato, N.; Shimose, S.; Numata, K.; Kodama, Y.; Ohkawa, K.; Kuzuya, T.; Ikeda, M.; Kooka, Y.; Aikata, H.; Hiraoka, A.; Moriguchi, M.; Fujiwara, K.; Suda, G.; Mochida, S.; Ogasawara, S.; Yamamoto, K.; Kudo, M.
Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients (P) progressed to atezolizumab plus bevacizumab (AB)

仑伐替尼（L）与索拉非尼（S）在进展至阿替利珠单抗联合贝伐珠单抗（AB）方案后的肝细胞癌（HCC）患者（P）中的二线治疗

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Persano, M.; Rimini, M.; Tada, T.; Suda, G.; Shimose, S.; Kudo, M.; Yoo, C.; Cheon, J.; Finkelmeier, F.; Lim, H. Y.; Presa, J.; Rossari, F.; Amadeo, E.; Vitiello, F.; Camera, S.; Foti, S.; Mascia, L.; Scartozzi, M.; Cascinu, S.; Gardini, A. Casadei
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab
SCIENTIFIC REPORTS
IF3.9
2024-08-301
OAAI
Rimini, Margherita; Montes, Margarida; Amadeo, Elisabeth; Vitiello, Francesco; Kudo, Masatoshi; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Lonardi, Sara; Finkelmeier, Fabian; Salani, Francesca; Antonuzzo, Lorenzo; Marra, Fabio; Iavarone, Massimo; Cabibbo, Giuseppe; Foschi, Francesco Giuseppe; Silletta, Marianna; Sacco, Rodolfo; Rapposelli, Ilario Giovanni; Scartozzi, Mario; Nicoletta, Pella; Aldrighetti, Luca; Persano, Mara; Camera, Silvia; Rossari, Federico; Foti, Silvia; Kumada, Takashi; Hiraoka, Atsushi; Iwamoto, Hideki; Rizzato, Mario Domenico; Himmelsbach, Vera; Masi, Gianluca; Corradi, Mattia; Celsa, Ciro; Fabio, Conti; Frassineti, Giovanni Luca; Cascinu, Stefano; Casadei-Gardini, Andrea; Presa, Jose
Evaluation of the associations of interlukin-7 genetic variants with toxicity and efficacy of immune checkpoint inhibitors: A replication study of a Japanese population, based on the findings of a European genome-wide association study

评估interlukin-7遗传变异与免疫检查点抑制剂毒性和疗效的相关性: 基于欧洲全基因组关联研究结果的日本人群的复制研究

HEPATOLOGY RESEARCH
IF3.4
2024-07-111
PRE
Miyamoto, Hideaki; Kondo, Yasuteru; Itobayashi, Ei; Uehara, Masayoshi; Hiraoka, Atsushi; Kudo, Masatoshi; Kakizaki, Satoru; Kagawa, Tatehiro; Miuma, Satoshi; Suzuki, Takanori; Sugi, Kazuhiro; Suyama, Koichi; Beppu, Toru; Toyoda, Hidenori; Yoshiji, Hitoshi; Uojima, Haruki; Miyase, Shiho; Inoue, Kaori; Tamori, Akihiro; Ito, Takanori; Shimose, Shigeo; Suda, Goki; Hayashi, Tsuguru; Onishi, Masaya; Narahara, Satoshi; Watanabe, Takehisa; Iwatsuki, Masaaki; Fukushima, Satoshi; Tanaka, Yasuhito

研究方向

暂未获取到该数据
H
Hideki Iwamoto
H 指数:39论文数:338被引数:5,435
T
Takumi Kawaguchi
H 指数:61论文数:513被引数:2.4万
T
Takashi Niizeki
H 指数:31论文数:153被引数:2,491
T
Tomotake Shirono
H 指数:21论文数:79被引数:1,358
T
Toshifumi Tada
H 指数:54论文数:455被引数:1.3万
T
Takuji Torimura
H 指数:58论文数:471被引数:1.3万
H
Hironori Koga
H 指数:47论文数:258被引数:8,681
A
Atsushi Hiraoka
H 指数:49论文数:543被引数:1.0万
G
Goki Suda
H 指数:34论文数:227被引数:3,375
S
Stefano Cascinu
H 指数:80论文数:1,593被引数:2.8万